Table 1.
Comparison of the clinical characteristics of pulmonary arterial hypertension and non-pulmonary hypertension groups
| Characteristics at the time of screening | PAH | Non-PH | P value |
|---|---|---|---|
| (n = 27) | (n = 34) | ||
| Mean ± SD or n (%) | Mean ± SD or n (%) | ||
| Age at disease onset, years a | 52.9 ± 14.7 | 48.6 ± 13.2 | 0.256 |
| Age at study, years | 66.8 ± 8.3 | 61.2 ± 11.9 | 0.033 |
| Disease duration at study, years | 14.9 ± 12.6 | 12.8 ± 10.4 | 0.566 |
| 13.0 (3.2-21.9)b | 10.3 (4.4-18.2)b | ||
| Female | 25 (93) | 16 (76) | 0.027 |
| SSc subtypes | |||
| Limited | 23 (85) | 27 (79) | 0.560 |
| Diffuse | 4 (15) | 7 (21) | |
| Telangiectasia | 24 (89) | 23 (68) | 0.049 |
| Antibodies | |||
| ANA | 24 (89) | 27 (90) | 0.617 |
| Anti-Scl70 | 1 (4) | 3 (10) | 0.373 |
| Anti-cent | 17 (63) | 11 (32) | 0.017 |
| NT-proBNP, pg/mL | 1,619.6 ± 2,063.6 | 401.3 ± 689.4 | <0.0001 |
| 841 (531.3-2,022.1)b | 143.6 (83.3-414.2)b | ||
| Serum urate, mg/100 mL | 6.7 ± 2.2 | 5.6 ± 1.8 | 0.038 |
| 6MWD, m | 310.4 ± 115.8 | 411.0 ± 114.2 | 0.003 |
aDisease onset defined as the date of first non-Raynaud’s symptom. bMedian (interquartile range). 6MWD, six-minute walk distance; ANA, anti-nuclear antibody; anti-cent, anti-centromere antibody; anti-Scl70, anti-topoisomerase-1 antibody; NT-proBNP, N-terminal pro-B type natriuretic peptide; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; SD, standard deviation; SSc, systemic sclerosis.